Literature DB >> 15161593

[Overall long-term survival in lung cancer analyzed in 610 unselected patients].

J Sánchez de Cos Escuín1, C Disdier Vicente, J Corral Peñafiel, J A Riesco Miranda, M A Sojo González, J F Masa Jiménez.   

Abstract

INTRODUCTION AND
OBJECTIVES: Many studies of lung cancer survival are carried out in patients selected for certain features that usually influence prognosis favorably. The objective of this study was to assess the overall survival of unselected patients with a diagnosis of lung cancer in our practice. PATIENTS AND METHODS: We studied 610 patients for whom survival information was available, a population comprising 88% of the 694 with lung cancer diagnosed in our hospital from 1991 through 1998. The variables analyzed for their correlation with survival were age, sex, histology, tumor-node-metastasis (TNM) stage, treatment, and time of diagnosis (with patients grouped by 2-year periods).
RESULTS: The cases of 596 men and 14 women with a mean age of approximately 67 years were studied. Small cell tumors were found in 141, non-small cell tumors in 447, and other tissue types in 22. Surgical excision was carried out on 118 (19.3%), and treatment was confined to control of symptoms for 6.4% of the patients with small cell tumors and 40.5% of those with non-small cell cancer. Symptomatic treatment alone was more common for patients older than 70 years (52.5%) and less common during the last 2 years of the study period (1997-1998: 19%). Overall 5-year survival was 7.9% (2.8% in small cell cancer and 9.4% in non-small cell cancer). Survival rates were lower in patients over 70 years of age. Significant differences in survival were seen for successive TNM stages, with the exception of IIIA and IIIB. The 1997-1998 period saw better survival rates, at 40.8% after 1 year and 11.2% after 5 years.
CONCLUSIONS: The survival rates in lung cancer patients in our hospital practice are low because the rate of surgical resections is low owing to the high percentage of cases found in advanced stages. Our observations are similar to those reported from other European countries.

Entities:  

Mesh:

Year:  2004        PMID: 15161593

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  5 in total

Review 1.  Patients with single brain metastasis from non-small cell lung cancer equally benefit from stereotactic radiosurgery and surgery: a systematic review.

Authors:  Hong Qin; Cancan Wang; Yongyuan Jiang; Xiaoli Zhang; Yao Zhang; Zhihua Ruan
Journal:  Med Sci Monit       Date:  2015-01-12

2.  SIRT3 acts as a novel biomarker for the diagnosis of lung cancer: A retrospective study.

Authors:  Feng Tao; Chao Gu; Na Li; Ying Ying; Yongzhi Feng; Dan Ni; Qi Zhang; Qinfeng Xiao
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

3.  Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine.

Authors:  Sevket Ozkaya; Serhat Findik; Adem Dirican; Atilla Güven Atici
Journal:  Exp Ther Med       Date:  2012-09-18       Impact factor: 2.447

4.  Burden of disease due to cancer in Spain.

Authors:  Nerea Fernández de Larrea-Baz; Elena Alvarez-Martín; Consuelo Morant-Ginestar; Ricard Gènova-Maleras; Angel Gil; Beatriz Pérez-Gómez; Gonzalo López-Abente
Journal:  BMC Public Health       Date:  2009-01-30       Impact factor: 3.295

5.  Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer.

Authors:  Jingjing Wang; Yanlin Wu; Mei Dong; Xiaohui He; Ziping Wang; Junling Li; Yan Wang
Journal:  Anticancer Drugs       Date:  2016-03       Impact factor: 2.248

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.